Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBITDA Margin for 6 consecutive years, with 671.86% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 106256.0% to 671.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1328.77% through Dec 2025, up 16093.0% year-over-year, with the annual reading at 1328.77% for FY2025, 16093.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 671.86% at Caribou Biosciences, up from 1250.91% in the prior quarter.
  • The five-year high for EBITDA Margin was 41.62% in Q3 2023, with the low at 2033.18% in Q2 2025.
  • Average EBITDA Margin over 5 years is 1020.18%, with a median of 825.1% recorded in 2021.
  • The sharpest move saw EBITDA Margin crashed -161728bps in 2024, then skyrocketed 106256bps in 2025.
  • Over 5 years, EBITDA Margin stood at 727.39% in 2021, then increased by 1bps to 717.01% in 2022, then tumbled by -31bps to 941.37% in 2023, then tumbled by -84bps to 1734.42% in 2024, then surged by 61bps to 671.86% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 671.86%, 1250.91%, and 2033.18% for Q4 2025, Q3 2025, and Q2 2025 respectively.